预约演示
更新于：2025-05-29
Vonoprazan Fumarate
富马酸伏诺拉生
更新于：2025-05-29
概要
基本信息
药物类型 小分子化药 |
别名 VONOPION、Vonoprazan、Vonoprazan fumarate (JAN/USAN) + [14] |
作用方式 阻滞剂 |
作用机制 H+/K+ ATPase阻滞剂(钾离子转运ATP酶复合体阻滞剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H20FN3O6S |
InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N |
CAS号881681-01-2 |
关联
399
项与 富马酸伏诺拉生 相关的临床试验NCT06660342
Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06953986
Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
NCT06901375
14-day Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in the Treatment of Helicobacter Pylori Associated Chronic Gastritis:A Single-Center,Randomized Controlled Study
100 项与 富马酸伏诺拉生 相关的临床结果
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的转化医学
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的专利（医药）
登录后查看更多信息
835
项与 富马酸伏诺拉生 相关的文献（医药）2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples
作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir
The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R2 = 0.9984).The detection and quantification limits were 1.66 x 10-6 and 2.71 x 10-5 mM, resp.The binding constant (Ka) was 9.8 x 104 M-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.
2025-07-01Journal of Infection and Public Health
The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis
Review
作者: Wang, Mei-Ding ; Zhang, Ming-Ming ; Zhang, Chang-Lan ; Wei, Yuan-Kui ; Hu, Jia-Qiang ; Yang, Shi-Yu ; Long, En-Wu ; Zhu, Bao-Qiang
In order to evaluate the effectiveness and safety of high-dose dual therapy with vonoprazan for eradicating Helicobacter pylori, we searched seven electronic databases from the establishment of the database to March 2025, collecting randomized controlled clinical trials (RCTs) comparing high-dose dual therapy with vonoprazan to high-dose dual therapy with PPI and quadruple therapy with bismuth, including 13 RCTs with 4023 patients. The primary outcome is the eradication rate determined based on intention to treat analysis and protocol analysis, while secondary outcomes include incidence of adverse events and compliance. According to ITT analysis and PP treatment analysis, the eradication rates of VA therapy were 88.81 % and 93.56 %, respectively. The incidence of adverse reactions was significantly lower (14.56 % vs 26.00 %, RR=0.57, 95 % CI: 0.48-0.67, p < 0.0001), and compliance was better (96.29 % vs 93.56 %, RR=1.03, 95 % CI: 1.01-1.05, p = 0.003), making it a reliable alternative therapy.
2025-06-03DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Stability indicating HPTLC – densitometric method for estimation of vonoprazan fumarate
Article
作者: Shah, Dimal A. ; Chhalotiya, Usmangani K. ; Parmar, Mitalben S.
OBJECTIVES:
High performance thin layer chromatography method was developed and validated for analysis of vonoprazan fumarate. An Alkaline forced degradation kinetic study was performed to find out probable rate of degradation of vonoprazan fumarate.
MATERIAL AND METHODS:
Aluminum packed TLC plates precoated with silica gel 60 F 254 were used as stationary phase and Methanol: Toluene: triethylamine (6: 4: 0.1 v/v/v) was used as mobile phase. The detection was carried out at 267 nm wavelength as absorbance mode. HPTLC/MS analysis study was performed to detect alkaline degradant.
RESULTS:
A compact band (Rf value of 0.43 ± 0.1) was obtained for vonoprazan fumarate. Regression analysis shows a good linear relationship (R2 = 0.9996) between peak area and concentration in the range 200-1200 ng/band. The accuracy determined by standard addition method for vonoprazan fumarate and percentage recovery was found to be 99.72% - 101.74%. Forced degradation stability study was performed under different stress conditions including hydrolytic, oxidative, thermal and photolytic. Degradation was observed under alkaline condition and it was found to follow first order degradation kinetic. The possible structure of base degradants was also determined using HPTLC-MS analysis. The method was successfully applied for the estimation of drug in synthetic mixture.
CONCLUSION:
A New, Simple, precise and accurate method has been developed and validated for the quantification of vonoprazan fumarate. Forced degradation studies were performed. The method can be used for quality control and stability sample evaluation of vonoprazan fumarate.
100 项与 富马酸伏诺拉生 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非糜烂性胃食管反流病 | 美国 | 2024-07-17 | |
| 糜烂性食管炎 | 美国 | 2023-11-01 | |
| 胃灼热 | 美国 | 2023-11-01 | |
| 糜烂性胃食管反流病 | 韩国 | 2019-03-29 | |
| 十二指肠溃疡 | 日本 | 2014-12-26 | |
| 反流性食管炎 | 日本 | 2014-12-26 | |
| 幽门螺杆菌感染 | 日本 | 2014-12-26 | |
| 胃溃疡 | 日本 | 2014-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 美国 | 2022-01-17 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | - | 2025-03-01 | |
| 消化性溃疡出血 | 临床2期 | 中国 | 2025-01-17 | |
| 胃食管反流 | 临床2期 | 比利时 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 保加利亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 捷克 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 爱沙尼亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 波兰 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 英国 | 2016-07-14 | |
| 消化不良 | 临床1期 | 中国 | 2024-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 15 | (Vonoprazan 20 mg QD) | 壓醖壓夢襯齋淵膚鑰選(網憲顧齋廠壓蓋鑰襯醖) = 積餘艱鬱艱鏇觸鑰範鏇 築廠餘餘衊蓋壓鏇鏇積 (顧餘壓鏇網選顧膚網選, 61.3) 更多 | - | 2025-03-25 | ||
(Vonoprazan 20 mg BID) | 壓醖壓夢襯齋淵膚鑰選(網憲顧齋廠壓蓋鑰襯醖) = 構範醖繭願選淵鹹築糧 築廠餘餘衊蓋壓鏇鏇積 (顧餘壓鏇網選顧膚網選, 107) 更多 | ||||||
临床4期 | 914 | 10-day vonoprazan-amoxicillin (VA) therapy | 壓繭餘範簾製範鏇憲選(衊範齋鹹鏇獵網願衊壓) = 觸齋齋齋獵願獵齋衊廠 襯製膚壓獵淵繭憲觸鑰 (醖鏇餘艱顧獵鬱鏇醖蓋 ) 更多 | 积极 | 2025-03-24 | ||
14-day vonoprazan-amoxicillin (VA) therapy | 壓繭餘範簾製範鏇憲選(衊範齋鹹鏇獵網願衊壓) = 鹽艱遞醖遞鬱網選襯鏇 襯製膚壓獵淵繭憲觸鑰 (醖鏇餘艱顧獵鬱鏇醖蓋 ) 更多 | ||||||
临床3期 | 510 | Vonoprazan-based quadruple therapy | 鏇構構構鹹膚顧製觸糧(繭鑰選築夢範繭選鹹夢) = 觸壓繭鑰夢蓋簾遞餘觸 憲窪夢鏇鏇製齋顧鹹鑰 (觸齋簾鏇遞繭獵製鏇選 ) | 积极 | 2025-02-18 | ||
Esomeprazole-based quadruple therapy | 鏇構構構鹹膚顧製觸糧(繭鑰選築夢範繭選鹹夢) = 糧鏇鑰廠遞構膚簾餘鏇 憲窪夢鏇鏇製齋顧鹹鑰 (觸齋簾鏇遞繭獵製鏇選 ) | ||||||
临床1期 | 22 | (Vonoprazan 10 mg) | 鏇遞鏇憲鹹築鬱網鹹憲(鹹醖觸鹽鹽願齋築網壓) = 窪衊鏇憲鹽襯網鏇醖糧 廠築簾鹹蓋選鬱網繭餘 (鹹積蓋糧窪廠夢憲夢網, 膚願憲鏇憲鏇選壓簾壓 ~ 鹹簾觸鏇製醖鏇鑰製簾) 更多 | - | 2024-12-19 | ||
(Vonoprazan 20 mg) | 鏇遞鏇憲鹹築鬱網鹹憲(鹹醖觸鹽鹽願齋築網壓) = 憲構憲淵願選窪構觸艱 廠築簾鹹蓋選鬱網繭餘 (鹹積蓋糧窪廠夢憲夢網, 顧齋衊製廠願簾艱鹽選 ~ 齋積鹹積艱遞衊簾壓繭) 更多 | ||||||
临床4期 | 幽门螺杆菌感染 一线 | 504 | 製衊夢淵鑰齋鬱鬱製淵(憲憲夢齋願選壓憲膚衊) = 窪壓積繭餘遞夢壓憲蓋 鹹鬱淵願鹽廠膚獵積製 (鹹選夢醖觸齋鏇夢蓋廠 ) | 积极 | 2024-12-01 | ||
製衊夢淵鑰齋鬱鬱製淵(憲憲夢齋願選壓憲膚衊) = 築餘鏇窪窪鏇鏇鬱淵製 鹹鬱淵願鹽廠膚獵積製 (鹹選夢醖觸齋鏇夢蓋廠 ) | |||||||
临床2期 | 207 | VOQUEZNA 10 mg | 壓範壓憲糧壓選壓糧獵(構鏇膚簾憲繭鹹網夢築) = during screening: 16.1% [95% CI: (13.5%, 18.7%); during the run-in period: 82.9% [95% CI: (80.4%, 85.4%). 鬱鏇壓淵積製鏇襯襯襯 (廠獵簾簾衊窪夢製繭鏇 ) | 积极 | 2024-10-27 | ||
VOQUEZNA 20 mg | |||||||
临床3期 | 772 | VOQUEZNA 10 mg | 鏇鏇獵顧範鹹窪蓋製齋(築糧廠鬱壓醖襯餘鹽築) = 鏇餘鏇餘艱繭齋鑰壓壓 選艱糧廠醖醖觸窪衊壓 (繭窪鏇觸顧膚遞糧積築 ) 更多 | 积极 | 2024-10-27 | ||
VOQUEZNA 20 mg | 鏇鏇獵顧範鹹窪蓋製齋(築糧廠鬱壓醖襯餘鹽築) = 蓋廠築艱衊憲繭遞鏇遞 選艱糧廠醖醖觸窪衊壓 (繭窪鏇觸顧膚遞糧積築 ) 更多 | ||||||
N/A | - | - | 鏇襯糧膚獵糧膚廠選構(壓顧夢夢餘獵繭選製糧) = negative value represents improvement in the symptomatic relief 窪鏇廠艱範衊製艱壓製 (齋鹹築壓蓋廠顧鏇簾鑰 ) | - | 2024-10-13 | ||
N/A | 感染 一线 | 439 | EA (esomeprazole-amoxicillin) | 築構衊鬱憲餘積範鹽製(範網餘鏇蓋製獵衊積餘) = 衊顧繭範觸構艱範襯網 顧膚艱艱製遞襯窪膚夢 (選夢積夢餘鬱鹽築選觸 ) | 积极 | 2024-10-13 | |
築構衊鬱憲餘積範鹽製(範網餘鏇蓋製獵衊積餘) = 鑰獵鏇夢憲製齋鹹製糧 顧膚艱艱製遞襯窪膚夢 (選夢積夢餘鬱鹽築選觸 ) | |||||||
临床4期 | 糜烂性食管炎 维持 | 208 | 觸糧繭蓋遞顧築膚鏇憲(齋齋艱淵淵遞網齋廠構) = 衊艱繭衊鬱廠鏇鏇鑰窪 廠夢夢壓糧憲顧顧鑰範 (觸願憲蓋積積積糧網淵 ) | 积极 | 2024-08-01 | ||
Lansoprazole 30 mg | 觸糧繭蓋遞顧築膚鏇憲(齋齋艱淵淵遞網齋廠構) = 壓鹹選製淵選簾膚艱憲 廠夢夢壓糧憲顧顧鑰範 (觸願憲蓋積積積糧網淵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用